In this article, we examine the research on sofosbuvir with a bibliometric analysis of global research production. The study of sofosbuvir has been a field of intense research in the past few years, with Latin American contributions playing a modest role. With continued drug development and approval of hepatitis C antivirals, research is expected to increase. Our findings will assist scholars and policy makers in their efforts to improve scientific research policies, with the goal of maximizing the access to treatments, especially in low and middle-income countries.
Introduction
Hepatitis C virus (HCV) has a major impact on public health, with around 170 million people in the world being affected 1 . In Latin America, the prevalence of hepatitis C has been estimated to be at around 1.6% of the adult population, and the most common genotypes are 1 and 3 2, 3 . The new treatments for HCV include direct-acting antivirals (DAAs), which shorten length of therapy, improve sustained virologic response rates, and minimize side effects 4 .
Sofosbuvir is one of the most important DAAs in the market today, but high prices have led to a large increase in spending by health systems and can be a barrier to rapid global treatment, especially in low and middle-income countries 5 . The identification of global research on DAAs might lead to new insights into the treatments of HCV and suggest research directions.
Based on the above, our study aimed to identify and explore the worldwide development of sofosbuvir research.
Methods
We performed a bibliometric analysis using the original articles indexed in Web of Science. The search strategy used the following MeSH and non-MeSH terms in the title field: Sofosbuvir, Sovaldi, PSI 7977, and GS 7977. The validity of the search strategy was tested by manually reviewing retrieved articles. Bibliometric indicators were investigated by analyzing annual research output, languages, countries, journals, authors, institutions, and citations. Indicators were analyzed with the option "Analyze Results" and "Create Citation Report" in Web of Science. Author co-citation analysis (ACA) was presented as network visualization map using VOSviewer (version 1.6.4) techniques 6 . (27) 
Results

A total of
Conclusions
According to our bibliometric analysis, the study of sofosbuvir has been a field of intense research in the past few years. Developed countries have had an enormous impact on the global research in the field. Recently, interest has focused on the use of sofosbuvir to treat Zika infection, and an important contribution to the body of sofosbuvir research has been supported by its manufacturer. With continued drug development and approval of hepatitis C antivirals, research is expected to continue increasing. 
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As sofosbuvir became an antiviral of major interest, not only towards HCV and ZIKV, but also for Dengue virus (DENV) ( ) -my suggestion is to compare https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524696/ the studies on the pharmacology of this drug on HCV and Flavivirus members. The study on ZIKV and sofosbuvir cited in this manuscript ( ) was preceded by a https://www.nature.com/articles/srep40920 pre-print, which was the first contribution to open the field of sofosbuvir against flaviviruses ( https://www.biorxiv.org/content/early/2016/07/06/061671; https://www.the-scientist.com/?articles.view/articleNo/46585/title/Sofosbuvir-Shows-Anti-Zika-Activity-In-Vitro/ ) -around six months after the ZIKV outbreak. I presume that the proposed comparison will demonstrate the installed capacity of response to novel (re)emergent viruses in Latin America.
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